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Background: Vasospasm-related delayed cerebral ischemia (DCI) significantly impacts on outcome after aneurysmal
subarachnoid hemorrhage (SAH). Erythropoietin (EPO) may reduce the severity of cerebral vasospasm and improve
outcome, however, underlying mechanisms are incompletely understood. In this study, the authors aimed to
investigate the effect of EPO on cerebral metabolism and brain tissue oxygen tension (PbtO2).
Methods: Seven consecutive poor grade SAH patients with multimodal neuromonitoring (MM) received systemic
EPO therapy (30.000 IU per day for 3 consecutive days) for severe cerebral vasospasm. Cerebral perfusion pressure
(CPP), mean arterial blood pressure (MAP), intracranial pressure (ICP), PbtO2 and brain metabolic changes were
analyzed during the next 24 hours after each dose given. Statistical analysis was performed with a mixed effects
model.
Results: A total of 22 interventions were analyzed. Median age was 47 years (32–68) and 86% were female. Three
patients (38%) developed DCI. MAP decreased 2 hours after intervention (P< 0.04) without significantly affecting
CPP and ICP. PbtO2 significantly increased over time (P< 0.05) to a maximum of 7 ± 4 mmHg increase 16 hours
after infusion. Brain metabolic parameters did not change over time.
Conclusions: EPO increases PbtO2 in poor grade SAH patients with severe cerebral vasospasm. The effect on
outcome needs further investigation.
Keywords: Cerebral microdialysis, Erythropoietin, Multimodality monitoring, Subarachnoid hemorrhageBackground
Vasospasm-related delayed cerebral ischemia (DCI) is
common and significantly impacts on outcome after
aneurysmal subarachnoid hemorrhage (SAH). [1] Under-
lying mechanisms including inflammation, oxidative dis-
tress and apoptosis may lead to secondary brain tissue
damage. [2] Strategies to prevent and treat cerebral vaso-
spasm include hyperdynamic therapy and calcium chan-
nel blockers, however still remain suboptimal. [1] Other
prophylactic agents such as endothelin A receptor
antagonists were effective in experimental and animal* Correspondence: raimund.helbok@uki.at
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reproduction in any medium, provided the orsettings but failed to improve outcome in human trials
[3-6]. There is some evidence that acute erythropoietin
(EPO) treatment may reduce the severity of cerebral
vasospasm and eventually improve outcome in SAH
patients [7,8]. Underlying mechanisms extend far beyond
erythropoiesis: EPO may enhance neurogenesis, decrease
inflammation and inhibit apoptosis especially in the
damaged brain where EPO receptors are highly
expressed [9,10]. Timing of EPO treatment in the early
phase of SAH may be crucial [7,8], however, the acute
effect of EPO on brain homeostasis in severe cerebral
vasospasm has not been elucidated so far.
In this study we sought to describe the effect of EPO
treatment on cerebral perfusion pressure (CPP), brainLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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SAH patients with severe cerebral vasospasm.
Methods
Patient selection and data collection
Between April 2010 and March 2011 seven consecutive
poor grade SAH patients with multimodal neuromonitor-
ing (MM) receiving erythropoietin as compassionate treat-
ment for severe cerebral vasospasm were studied. All
patients were admitted to the Neurological Intensive Care
Unit at Innsbruck Medical University. The clinical care
for SAH patients conforms to guidelines set forth by the
American Heart Association [1]. All patients received con-
comitant statin therapy and were on midazolame, sufenta-
nil and/ or ketamine continuous infusions at the days of
intervention. Severe vasospasm was defined by mean tran-
scranial doppler (TCD) velocity >180 cm/sec and a Linde-
gaard ratio >3 when conventional treatment (continuous
intravenous nimodipine application and hemodynamic
augmentation with CPP target >80 mmHg) failed. DCI
was defined as appearance of new infarction on CT that
was judged by an independent radiologist to be attribut-
able to cerebral vasospasm.
Intervention
EPO (Epoetin alfa, ErypoW, Janssen-Cilag Pharma, Vienna,
Austria) 30.000 IU diluted to 50 ml of normal saline was
administered as infusion over 30 min every day for 3 con-
secutive days immediately after severe vasospasm was
diagnosed. The decision to start the intervention was
made by the neurointensivist in charge (ES, BP, RB, RH).
In one patient a single dose was given, another patient
received two sets of interventions at intervals of 7 days,
leading to 22 interventions analyzed.
Neuromonitoring, data collection and ethical approval
Based on the clinical and imaging criteria, the patient
underwent monitoring of cerebral metabolism, brain tis-
sue oxygenation (PbtO2), and ICP according to local insti-
tutional protocol which is in compliance with the Helsinki
Declaration and has been approved by the local ethics
committee (UN3898 285/4.8). Written informed consent
was obtained according to federal regulations. Through a
right frontal burr hole, a triple-lumen bolt was affixed to
insert a Licox Clark-type probe (Integra Licox Brain
Oxygen Monitoring, Integra NeuroSciences, Ratingen,
Germany) to measure PbtO2 and an ICP parenchymal
probe (NEUROVENT_P-TEMP, Raumedic, Münchberg,
Germany). In addition, a high cut-off brain microdialysis
catheter (CMA 71, Dipylon Medical, Solna, Sweden) was
tunneled and inserted into the brain parenchyma for
hourly assessment of brain metabolism. Isotonic perfusion
fluid (Perfusion Fluid CNS, Dipylon Medical) was pumped
through the system at a flow rate of 0.3 μl/min. Hourlysamples were analyzed with CMA 600 Microdialysis
Analyzer (CMA/Microdialysis, Solna, Sweden) for cerebral
extracellular glucose, pyruvate, and lactate concentrations.
At least 1 h passed after the insertion of the probe and the
start of the sampling, to allow for normalization of
changes due to probe insertion. The location of the moni-
toring catheters in the white matter of the right frontal
lobe was confirmed by brain CT scan immediately after
the procedure. All continuously measured parameters
were saved on a 3 min average interval using our patient
data management system (Centricity* Critical Care 7.0
SP2, GE Healthcare Information Technologies, Dornstadt,
Germany). Transcranial Doppler sonography was per-
formed using the DWL Doppler-Box system (Compume-
dics, Singen Germany). Data on CPP, ICP and MAP were
available during all interventions, PbtO2 and microdialysis
in 14 and 18 observations, respectively.
Statistic
Continuous variables were assessed for normality. Nor-
mally distributed data were reported as mean and stand-
ard error of mean, nonparametric data as median and
interquartile range (IQR), unless indicated otherwise.
Categorical variables were reported as count and propor-
tions in each group. Hourly recorded brain metabolic
parameters were averaged for 6 hours episodes, and con-
tinuously recorded parameters (PbtO2, CPP, MAP, ICP)
for 2 hours episodes. Baseline values were calculated ac-
cordingly and changes from baseline were analyzed:
multiple observations per subject were handled by using
generalized estimating equations with an autoregressive
working correlation matrix. For all tests, significance
was set at P< 0.05. All analyses were performed with
SPSS V19.0 (SPSS Inc., Chicago, Illinois).
Results
General characteristics and outcome
Baseline characteristics are described in the Table 1. Me-
dian patient age was 47 years (IQR:32–68) and six of
seven were female. None of the patients had a history of
malignancy or thrombembolism and no thromboembolic
events occurred during hospitalization. All patients devel-
oped severe vasospasm in the anterior circulation of the
aneurysm site and received Erythropoietin (EPO) at a me-
dian of 9 days (IQR:6–12) after ictus. None of the patients
died during hospitalization and 3 patients (38%) developed
DCI with evidence of new cerebral infarctions at the site
of the ruptured aneurysm distant (>3 cm) to the neuro-
monitoring probes. In these patients cranial CT scan had
been performed after the observation period.
Effect of erythropoietin on physiologic variables
Baseline CPP and MAP were 86 mmHg (IQR:77–95)
and 99 mmHg (IQR:85–105), respectively, and ICP was
Table 1 Characteristics of EPO patient cohort








ICH on admission CT
1 53 F 4 3 15 1 no yes
2a 40 F 5 1 12 0 no yes
2b 40 F 5 1 12 0 no yes
3 69 F 4 3 25 8 no no
4 32 F 5 4 18 3 no no
5 29 M 5 4 14 4 no no
6 68 F 5 3 30 0 no no
























R MCA R frontal 2 154 230 8 1 R MCA,R
ACA
5
R MCA R frontal 2 217 101 2 1 R MCA 5
R MCA R frontal 2 217 101 11 0 0 5
PICA r R frontal 1 299 120 16 0 0 4
R PCoA R frontal 1 154 144 12 0 0 3
ACoA R frontal 1 96 144 9 0 0 2
R MCA R frontal 2 213 115 9 0 0 3




R= right; L = left; H&H=Hunt-Hess Grade; SAH sum score grades the amount of blood in 10 basal cisterns and fissures (0 = no SAH, 1 = small SAH, 2 =moderate
SAH, 3 = completely filled with SAH) by adding each of the 10 individual cistern scores (range 0–30); IVH sum score grades the amount of blood in the right and
left lateral, third and fourth ventricle (0 = no blood, 1 = sedimentation, 2 = partly filled, 3 = completely filled) by adding each of the 4 individual ventricle scores
(range 0–12); ACoA= anterior communicating artery; PCoA =posterior communicating artery; MCA=middle cerebral artery; SBP = systolic blood pressure;
DCI = delayed cerebral ischemia; CT = computed tomography; SAH= subarachnoidal hemorrhage; ICH= intracerebral hemorrhage; IVH = intraventricular
hemorrhage; mRS =modified Rankin Scale.
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decreased to 92 mmHg (IQR:82–101) 2 hours after
intervention (P< 0.04) returning to baseline for the
remaining 24 hours without significantly affecting CPP
and ICP (Figure 1, Panel A-C).Effect of erythropoietin on brain tissue oxygen tension
and brain metabolism
PbtO2 (baseline 29 mmHg, IQR:22–32) significantly
increased over time by 4± 3 mmHg (mean increase com-
pared to baseline) to a maximum of 7 ± 4 mmHg increase
16 hours after start of intervention (P< 0.05) (Figure 1,
Panel D). All patients had an increase in PbtO2 at a certain
point during the follow up time of 24 hours. Accounting
for the EPO dose given (1st, 2nd, 3rd) per patient did not
affect the observed result. Hemoglobin (baseline 9.5 mg/
dL, IQR:9–11.5), body temperature (36.8°C, IQR: 36,6-
37.1) and SpO2 (96%, IQR:95–97) remained stable and
respirator settings were not changed during the 24
h-observation periods.Baseline brain metabolic data showed an increased me-
dian LPR (32, IQR:29–38) and slightly decreased brain glu-
cose (1.1 mmol/L, IQR:0.8-2.8). Median brain lactate and
pyruvate was 4.6 mmol/L (IQR:2.4-6.1) and 131 μmol/L
(IQR:88–158), respectively. There was no significant change
in brain lactate, pyruvate and brain glucose during the ob-
servation periods (Figure 2, Panel A and B).Discussion
Our findings suggest that high-dose systemic EPO treat-
ment increases brain tissue oxygen tension in patients
with severe vasospasm after SAH. The present data are
of potential importance because they support the hy-
pothesis of a beneficial effect of high-dose systemic EPO
beyond erythropoeisis on human brain tissue.
Vasospasm occurs in up to 70% of aSAH patients, leads
to decreased oxygen delivery with tissue hypoxemia, even-
tually resulting in brain tissue ischemia [1]. In in-vivo
models of cerebral ischemia EPO and its receptor are
highly expressed [11-13]. Experimental and clinical studies
Figure 1 Two-hourly averaged changes in cerebral perfusion pressure (CPP), mean arterial pressure (MAP), intracranial pressure (ICP)
and brain tissue oxygen tension (PbtO2) following EPO (30.000 IU over 30 min) therapy, (mean± SEM). * P< 0.05
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flammation, enhancing neurogenesis, inhibiting apoptosis
and limiting SAH-induced oxidative damage especially in
vulnerated brain tissue [9,10,14,15]. The effect of EPO on
brain tissue oxygen tension may be multifactorial as PbtO2
is considered as marker of oxygen delivery, diffusion and
consumption.
In an experimental model of ischemic tissue damage pre-
treatment with EPO improved microcirculation through
increased arteriolar and venular blood flow with consecu-
tive enhanced brain tissue oxygenation [16]. In this model,
the beneficial effect of EPO was antagonized by blockade of
NO synthase (NOS) activity, suggesting a link between
EPO and NO-dependent vasodilatory effects [16], which
has also been postulated in a rabbit SAH model of cerebral
vasospasm [17,18]. After acute brain injury in humans, a
strong correlation of PbtO2 and cerebral blood flow may
exist in certain circumstances [19]. This may explain our
findings of PbtO2-increase after EPO treatment, however,
we did not measure cerebral blood flow in our patients to
elaborate further on this finding. EPO may also enhanceangiogenesis and thereby increase the amount of oxygen
delivered to hypoxic tissue [20]. Proposed mechanisms in-
clude direct activation of endothelial cells by binding on the
EPO-receptor or via activation of the vascular endothelial
growth factor (VEGF)/VEGF receptor system [21]. In our
patients, this hypothesis is unlikely as an increase in PbtO2
was observed within hours.
Another potential mechanism how EPO may increase
PbtO2 is through its anti-inflammatory potency [22]. In
vivo attenuation of the inflammatory response was achieved
by EPO pretreatment in critically ischemic tissue with a sig-
nificant effect after 5 hours [16]. Reduced metabolic de-
mand and therefore oxygen consumption may eventually
result in increased brain tissue oxygen tension with a la-
tency of a few hours. Although we have not analyzed brain
extracellular parameters of inflammation in our patients,
the observed PbtO2 increase hours after EPO administra-
tion supports this hypothesis.
EPO did not improve brain metabolism, which repli-
cates a previous study on 73 aSAH patients receiving 3
doses of EPO-alpha 500 IU/kg/day early after the initial
Figure 2 Six-hourly averaged change in lactat-pyruvate ratio (LPR) and brain tissue glucose concentration following EPO (30.000 IU
over 30 min) therapy, (mean± SEM).
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at baseline in the absence of brain tissue hypoxia in our
patients suggests that an increase in PbtO2 may not ne-
cessarily translate into improved brain metabolism. The
effect of EPO on brain homeostasis in the setting of aSAH
patients with vasospasm-related ischemic pattern of brain
metabolic crisis (LPR> 40 and Glucose< 0.7 mmol/L
associated with PbtO2 <20 mmHg) would be of upmost
interest. However, it seems important that EPO treatment
has to be initiated in a timely fashion before ischemic
damage occurs [11]. Elevation of cerebral LPR may also be
explained by brain mitochondrial dysfunction [23], and
EPO restored brain mitochondrial function in an experi-
mental TBI model and may enhance cellular energy gen-
eration [10].
We used EPO as compassionate treatment in patients
with severe cerebral vasospasm after aSAH following an
institutional protocol. We carefully explore patients on
underlying malignant diseases or risk of thromboembol-
ism to limit this potential side effect of EPO [24]. Like in
a previous trial including 80 aSAH patients, we used a
high dose EPO regimen (total average dose of 90.000 IU)
and did not observe any thromboembolic events [7].
Several limitations of the present study include a small
sample size, a retrospective observational study design, a
single institutional observation and lack of timed cranial
CT scans. In addition, we did not routinely perform
cerebral angiograms and the diagnosis of vasospasm was
based on TCD studies. Therefore we want to emphasize,
that in this pilot study we investigated the immediate
physiologic response of high dose EPO on brain homeo-
stasis in the setting of severe vasospasm. Moreover, we
did not measure reticulocyte count in our patients, how-
ever hemoglobin and MAP remained stable after EPO
treatment. Due to the small samples size a proper multi-
variate model could not be applied, however we did not
observe changes in confounding factors of PbtO2, e.g.
respirator settings. The ruptured aneurysm was located
in the posterior circulation in 2 patients and themonitoring probes were placed in the ispsilateral right
frontal white matter. We rarely consider invasive moni-
toring of regions in the occipital lobe or posterior fossa.
Because both patients had a high SAH sum score, ad-
mission global cerebral edema and developed general-
ized vasospasm, the apparently remote distance between
the vascular territory of the aneurysm bearing vessel and
monitoring probes is of minor significance.
In this pilot study we did not gather information on
cerebrovascular autoregulation and tissue enzyme activa-
tion which might also play a role in the EPO-related
increases in PbtO2. Noteworthy, it has been shown that
EPO can restore cerebral autoregulation after SAH
[7,25] leading to enhanced cerebral blood flow and oxy-
gen delivery to the brain. Also, EPO has been demon-
strated to attenuate ischemia induced apoptotic cell
death by modulation of the caspase cascade and may
therefore influence PbtO2 [16].
Conclusions
These preliminary data suggest a beneficial effect of
EPO in poor grade SAH patients with severe cerebral
vasospasm. Further studies in larger cohorts are needed
to evaluate the EPO effect on the long-term functional
outcome of SAH patients.
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